NEW YORK, Feb. 9, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NasdaqGM:ESPR) of the March 14, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all those who purchased Esperion common stock between August 18, 2015 and September 28, 2015 (the "Class Period"). The case, Dougherty v. Esperion Therapeutics, Inc. et al, No. 2:16-cv-10089 was filed on January 12, 2016, and has been assigned to Judge Arthur J. Tarnow.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by issuing materially false and misleading statements in connection with the Company's future prospects for their lead drug candidate ETC-1002, a drug designed to lower LDL-cholesterol levels. The FDA had encouraged Esperion to initiate a cardiovascular outcomes trial ("CVOT") and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion stated that the FDA had informed it that the Company did not have to complete a CVOT to gain approval of ETC-1002. However, in an Esperion news release that was released after market close on September 28, 2015, it was revealed that the FDA had encouraged the Company to initiate a CVOT to obtain approval.
On September 28, 2015, Esperion's stock closed at $35.09 per share. As a result of the news release, the Company's share price fell $16.76 per share the next day to close at $18.33 per share, a 47.7% decrease in share price.
Request more information now by clicking here: www.faruqilaw.com/ESPR . There is no cost or obligation to you.
If you invested in Esperion common stock between August 18, 2015 and September 28, 2015 and would like to discuss your legal rights, visit www.faruqilaw.com/ESPR. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Esperion's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 3rd Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP